Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Veronika Gebel"'
Autor:
Benedikt Jacobs, Veronika Gebel, Lukas Heger, Victoria Grèze, Hansjörg Schild, Diana Dudziak, Evelyn Ullrich
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Cellular therapy has entered the daily clinical life with the approval of CAR T cell therapeutics and dendritic cell (DCs) vaccines in the US and the EU. In addition, numerous other adoptive cellular products, including natural killer (NK) cells, are
Externí odkaz:
https://doaj.org/article/17797aafec86438e91508a05b6075534
Autor:
Stephan Müller, Tobias Bexte, Veronika Gebel, Franziska Kalensee, Eva Stolzenberg, Jessica Hartmann, Ulrike Koehl, Axel Schambach, Winfried S. Wels, Ute Modlich, Evelyn Ullrich
Publikováno v:
Frontiers in Immunology, Vol 10 (2020)
Autologous chimeric antigen receptor-modified (CAR) T cells with specificity for CD19 showed potent antitumor efficacy in clinical trials against relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL). Contrary to T cells, natural killer
Externí odkaz:
https://doaj.org/article/d8dae0285dea4bba84619752c586d5b2
Autor:
Julia Campe, Michael Hudecek, Csaba Miskey, Zoltán Ivics, Veronika Gebel, Lacramioara Botezatu, Winfried S. Wels, Evelyn Ullrich, Tobias Bexte, Lisa Marie Reindl
Publikováno v:
Blood. 138:2797-2797
Background: Natural Killer (NK) cells are known for their high intrinsic cytotoxic capacity. Recently, we and others showed that virally transduced NK cells equipped with a synthetic chimeric antigen receptor (CAR) targeting CD19 induced enhanced kil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebaa3edddb5691f85a7b44451ae73225
https://doi.org/10.1182/blood-2021-153999
https://doi.org/10.1182/blood-2021-153999
Autor:
Stephan, Müller, Tobias, Bexte, Veronika, Gebel, Franziska, Kalensee, Eva, Stolzenberg, Jessica, Hartmann, Ulrike, Koehl, Axel, Schambach, Winfried S, Wels, Ute, Modlich, Evelyn, Ullrich
Publikováno v:
Frontiers in Immunology
Autologous chimeric antigen receptor-modified (CAR) T cells with specificity for CD19 showed potent antitumor efficacy in clinical trials against relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL). Contrary to T cells, natural killer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7b4672ce25ba316c58a488c1156339b6
https://pubmed.ncbi.nlm.nih.gov/32117200
https://pubmed.ncbi.nlm.nih.gov/32117200